These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 23817368)
1. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Lewis JS; Wiederhold NP; Wickes BL; Patterson TF; Jorgensen JH Antimicrob Agents Chemother; 2013 Sep; 57(9):4559-61. PubMed ID: 23817368 [TBL] [Abstract][Full Text] [Related]
2. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. Singh-Babak SD; Babak T; Diezmann S; Hill JA; Xie JL; Chen YL; Poutanen SM; Rennie RP; Heitman J; Cowen LE PLoS Pathog; 2012; 8(5):e1002718. PubMed ID: 22615574 [TBL] [Abstract][Full Text] [Related]
3. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait. Al-Baqsami ZF; Ahmad S; Khan Z Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126 [TBL] [Abstract][Full Text] [Related]
4. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Pham CD; Iqbal N; Bolden CB; Kuykendall RJ; Harrison LH; Farley MM; Schaffner W; Beldavs ZG; Chiller TM; Park BJ; Cleveland AA; Lockhart SR Antimicrob Agents Chemother; 2014 Aug; 58(8):4690-6. PubMed ID: 24890592 [TBL] [Abstract][Full Text] [Related]
5. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous Mutational Frequency and Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796 [TBL] [Abstract][Full Text] [Related]
7. Novel Hou X; Healey KR; Shor E; Kordalewska M; Ortigosa CJ; Paderu P; Xiao M; Wang H; Zhao Y; Lin LY; Zhang YH; Li YZ; Xu YC; Perlin DS; Zhao Y Emerg Microbes Infect; 2019; 8(1):1619-1625. PubMed ID: 31711370 [TBL] [Abstract][Full Text] [Related]
8. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Bizerra FC; Jimenez-Ortigosa C; Souza AC; Breda GL; Queiroz-Telles F; Perlin DS; Colombo AL Antimicrob Agents Chemother; 2014; 58(4):2438-40. PubMed ID: 24468776 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates. Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063 [TBL] [Abstract][Full Text] [Related]
10. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382 [TBL] [Abstract][Full Text] [Related]
11. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Garcia-Effron G; Lee S; Park S; Cleary JD; Perlin DS Antimicrob Agents Chemother; 2009 Sep; 53(9):3690-9. PubMed ID: 19546367 [TBL] [Abstract][Full Text] [Related]
12. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Beyda ND; John J; Kilic A; Alam MJ; Lasco TM; Garey KW Clin Infect Dis; 2014 Sep; 59(6):819-25. PubMed ID: 24879785 [TBL] [Abstract][Full Text] [Related]
13. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754 [TBL] [Abstract][Full Text] [Related]
14. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Thompson GR; Wiederhold NP; Vallor AC; Villareal NC; Lewis JS; Patterson TF Antimicrob Agents Chemother; 2008 Oct; 52(10):3783-5. PubMed ID: 18676885 [TBL] [Abstract][Full Text] [Related]
18. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. Pfaller MA; Castanheira M; Lockhart SR; Ahlquist AM; Messer SA; Jones RN J Clin Microbiol; 2012 Apr; 50(4):1199-203. PubMed ID: 22278842 [TBL] [Abstract][Full Text] [Related]
19. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia. Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020 [TBL] [Abstract][Full Text] [Related]
20. The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination. Healey KR; Nagasaki Y; Zimmerman M; Kordalewska M; Park S; Zhao Y; Perlin DS Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971865 [No Abstract] [Full Text] [Related] [Next] [New Search]